Here we demonstrate that the small molecule flavone derivative, voruciclib, a clinical stage CDK inhibitor, targets CDK9 with sub-nanomolar biochemical potency and represses expression of MCL-1 in multiple models of DLBCL. This evidence concerns the gene CDK9 and diffuse large B-cell lymphoma.